This cluster of papers focuses on the targeted degradation of specific proteins, particularly through the use of BET bromodomain inhibitors and PROTACs. The research explores the therapeutic potential of this approach, with a focus on histone recognition, small molecule inhibitors, and the role of epigenetic readers in transcriptional regulation. Additionally, it investigates the use of cereblon-dependent degradation and its implications for drug discovery.